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The inflammatory response is a critical molecular defense mechanism of the innate 
immune system that mediates the elimination of disease-causing bacteria. Repair of 
the damaged tissue, and the reestablishment of homeostasis, must be accomplished 
after elimination of the pathogen. The innate defense regulators (IDRs) are short cationic 
peptides that mimic natural host defense peptides and are effective in eliminating patho-
gens by enhancing the activity of the immune system while controlling the inflammatory 
response. Although the role of different IDRs as modulators of inflammation has been 
reported, there have been only limited studies of the signaling molecules regulated by 
this type of peptide. The present study investigated the effect of IDR-1002 on nuclear 
factor κB (NF-κB) and cAMP-response element-binding protein (CREB) transcription 
factors that are responsible for triggering and controlling inflammation, respectively, in 
macrophages. We found that TNF-α and COX-2 expression, IκBα phosphorylation, and 
NF-κB nuclear translocation were strongly inhibited in macrophages pre-incubated with 
IDR-1002 and then stimulated with lipopolysaccharide (LPS). IDR-1002 also increased 
CREB phosphorylation at Ser133 via activation of the p38/ERK1/2–MSK1 signaling 
pathways without detectable expression of the cytokines IL-4, IL-10, and IL-13 involved 
is suppressing inflammation or alternative activation. Transcriptional activation of NF-κB 
and CREB is known to require interaction with the transcriptional coactivator CREB-
binding protein (CBP). To test for CBP–NF-κB and CBP–CREB complex formation, 
we performed co-immunoprecipitation assays. These assays showed that IDR-1002 
inhibited the interaction between CBP and NF-κB in macrophages stimulated with LPS, 
which might explain the inhibition of TNF-α and COX-2 expression. Furthermore, the 
complex between CBP and CREB in macrophages stimulated with IDR-1002 was also 
inhibited, which might explain why IDR-1002 did not lead to expression of IL-4, IL-10, 
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and IL-13, even though it induced an increase in phospho-CREB relative abundance. 
In conclusion, our results indicated that IDR-1002 has a dual effect. On one hand, it 
inhibited NF-κB nuclear translocation through a mechanism that involved inhibition of 
IκBα phosphorylation, and on the other, it activated a protein kinase signaling cascade 
that phosphorylated CREB to selectively influence cytokine gene expression. Based on 
these results, we think IDR-1002 could be a potential good biopharmaceutical candidate 
to control inflammation.
Keywords: iDr, peptides, inflammation, macrophages, iκBα, nF-κB, creB, TnF-α
inTrODUcTiOn
The inflammatory response is one of the main defense mecha-
nisms of the innate immune system that is activated by host 
infection with microbial pathogens or tissue damage. This 
response is fundamental to identify and neutralize the causative 
agent and restore tissue homeostasis (1). However, in some cases, 
inflammation can be detrimental, especially when the control 
or resolution mechanisms fail, leading to chronic inflammatory 
conditions such as arteriosclerosis, insulin resistance, rheumatoid 
arthritis, and Alzheimer’s disease (2).
The balance between the inflammatory response and its reso-
lution is maintained in part by the activity of two transcription 
factors with opposite roles, the nuclear factor κB (NF-κB) and the 
cAMP-response element-binding protein (CREB). Activation 
of NF-κB induces expression of pro-inflammatory genes (e.g., 
TNF-α, IL-6, IL-8, and COX-2), while activation of CREB leads 
to gene expression of cytokines that have an anti-inflammatory 
role (e.g., IL-4, IL-10, and IL-13) (3, 4). NF-κB has five subu-
nits but the heterodimer of NF-κB, constituted of p65 and p50 
subunits, is one of the most studied active forms of this family of 
transcription factors (5, 6). When cells are not stimulated, NF-κB 
is anchored in the cytosol to IκBα protein. After stimulation, 
IκBα becomes phosphorylated, ubiquitinated, and degraded 
by the 26S proteosome. Degradation of IκBα releases NF-κB 
that is translocated to the nucleus where it initiates a complex 
transcriptional response (7). Once in the nucleus NF-κB can 
interact with a transcriptional coactivator CREB-binding protein 
(CBP) and initiate a distinct transcriptional pattern. Activation 
of NF-κB can also involve phosphorylation of several residues in 
the transactivation domain of p65 subunit, among which Ser536 
is well characterized (8–10).
cAMP-response element-binding protein is a cellular tran-
scription factor that belongs to the basic leucine-zipper domain 
family of proteins (11). This family is formed by dozens of pro-
teins, including CREB, the cAMP-response element modulator 
(CREM), and the activating transcription factor-1 (ATF-1). In 
cells activated by growth factors, hormones, lipopolysaccharide 
(LPS), and other stimuli (12, 13), CREB is phosphorylated at 
Ser133 by protein kinase A, protein kinase B (Akt), MSK, or 
other enzymes (14,  15). Phosphorylation at this residue pro-
motes CREB binding to transcriptional coactivator CBP, which 
can lead to displacement of NF-κB from the same interaction 
domain on CBP (16, 17). Formation of CREB–CBP complex 
promotes the expression of cytokines, typically involved in 
anti-inflammatory events or alternative activation of mono-
cytes, thereby suppressing expression of pro-inflammatory 
cytokines activated by the NF-κB–CBP complex (18). Although 
this mechanism has been widely proposed (19–22), other 
groups have reported no expression of genes when CREB is 
phosphorylated at Ser133 downstream of mitogen-activated 
protein kinase (MAPK) pathways (15, 23, 24). It may imply that 
control of inflammation by CREB phosphorylation does not 
necessarily involve the expression of anti-inflammatory genes 
induced by this transcription factor.
Innate defense regulator (IDR) peptides were designed 
from the natural theme of cationic host defense peptides (25) 
as an alternative to traditional anti-inflammatory and antimi-
crobial drugs. The immunomodulatory effects of IDRs have 
attracted the attention because of the worldwide problem of 
multiple antibiotic resistance in bacteria (26–28). In addition 
to downregulation of the pro-inflammatory response to bacte-
rial ligands, IDRs stimulate protective immunity (enhancing 
cellular recruitment and promoting differentiation of immune 
cells) leading to lowering of the bacterial burden without any 
direct interaction with bacteria (26–28). In addition to their 
anti-infective and anti-inflammatory effects due to modulation 
of the immune response, these peptides may also be considered 
good potential therapeutic candidates to combat chronic inflam-
mation associated with autoimmune diseases (29, 30). One of 
these peptides, IDR-1002, efficiently enhanced the immune 
response to eliminate Staphylococcus aureus and Escherichia coli 
from infected tissues, even when these bacterial pathogens were 
multi-resistant to antibiotics (26,  27). Moreover, in synovial 
fibroblasts, IDR-1002 effectively controlled inflammation by 
selectively modulating the expression of interleukin (IL)-1Ra 
and IL-10 and reducing NF-κB p50 nuclear translocation 
induced by IL-1β (29).
Although several studies have previously reported the poten-
tial beneficial effects of IDR-1002, the molecular transduction 
mechanisms involved in the IDR-1002 activity have not been 
well described to date (26, 27, 31, 32). Therefore, we focused our 
attention on the NF-κB and CREB transcription factors, because 
they are important in triggering and resolving the inflam-
matory response, respectively. We found that, in RAW264.7 
macrophages, stimulated with LPS IDR-1002 was able to inhibit 
NF-κB nuclear translocation by inhibiting IκBα degradation, 
leading to a reduction of cycloooxygenase-2 (COX-2), and 
TNF-α expression. Co-immunoprecipitation analysis of CBP–
NF-κB molecular complex showed that IDR-1002 inhibited the 
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interaction between CBP and NF-κB induced by LPS. We also 
observed that IDR-1002 induced high levels of CREB phospho-
rylation at Ser133 through activation of p38/ERK1/2–MSK1/2 
signaling pathways. Interestingly, we could not detect expression 
of the anti-inflammatory cytokines IL-4, IL-10, and IL-13, which 
are known to be regulated by CREB. By applying a similar co-
immunoprecipitation analysis, the molecular complex between 
CBP and CREB was not detected in macrophages stimulated with 
IDR-1002, which may explain the lack of anti-inflammatory gene 
expression.
MaTerials anD MeThODs
Media and chemicals
Innate defense regulator peptides (IDR) 1002 
(VQRWLIVWRIRK-NH2), HH2 (VQLRIRVAVIRA-NH2), 
and 1 (KSRIVPAIPVSLL-NH2) were synthesized using solid 
phase F-moc chemistry by CPC Scientific, Inc. (Sunnyvale, CA, 
USA) and were >95% pure. RPMI 1640 cell culture medium, 
Bradford reagent, bovine serum albumin (BSA), Wortmannin 
(inhibitor of PI3K), Akt IV (inhibitor of Akt), Rapamycin 
(inhibitor of p70S6K), SB216763 (inhibitor of GSK3), PD98059 
(inhibitor of ERK1/2), and Ro-318220 (inhibitor of MSK1) 
were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, 
USA). SB203580 (inhibitor of p38) and SP600125 (inhibitor 
of JNK) were purchased from Calbiochem (San Diego, CA, 
USA). Lymphoprep™ was purchased from Axis-Shield PoC AS 
(Oslo, Norway). Upon arrival, all inhibitors were solubilized in 
DMSO and stored in aliquots at −20°C. Newborn calf serum 
was acquired from Hyclone Laboratories, Inc. (South Logan, 
UT, USA). Penicillin G and streptomycin were purchased from 
Gibco-BRL (Gaithesburg, MD, USA). EDTA-free protease 
inhibitor cocktail (50×) was purchased from Roche Applied 
Science (Manheim, Germany). Antibodies against β-actin 
(Sc-47778), COX-2 (Sc-1747), GAPDH (Sc-25778), laminin 
A/C (6215), IκBα (Sc-203), and phospho-IκBα (Sc-52943) 
for the detection of phosphorylated Ser32 and Ser36, CREB-1 
(Sc-186), NF-κB p65 (Sc-8008), CBP (Sc-7300), anti-rabbit 
IgG-HRP (Sc-2004), rabbit anti-goat IgG-HRP (Sc-2768), and 
goat anti-mouse IgG-HRP (Sc-2031) were acquired from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies 
against the phosphorylated forms of CREB at Ser133 (9196), 
p38 at Thr180/Tyr182 (4511), NF-κB p65 at Ser536 (3033), 
GSK3α at Ser21 (9316), and GSK3β at Ser9 (9336) were pur-
chased from Cell Signaling Technology (Boston, MA, USA). 
Antibodies to detect phosphorylated MSK1 at Thr581 (AF2518) 
were purchased from R&D Systems (Minneapolis, MN, USA). 
Antibodies to detect the phosphorylated forms of IKKα and β 
at Thr23 were obtained from Santa Cruz Biotechnology (Cat. 
Sc-21660, Santa Cruz, CA, USA). Non-fat dry milk was acquired 
from Bio-Rad (California, CA, USA) and Luminol reagent from 
Millipore (Billerica, MA, USA).
cell line and culture conditions
The mouse leukemic monocyte macrophage cell line RAW 264.7 
used was obtained from the American Type Culture Collection 
(ATCC). This immortalized cell line was grown and maintained 
in RPMI medium supplemented with 10% FCS, unless otherwise 
noted.
isolation of human Peripheral Blood 
Mononuclear cells
Venous blood (20 ml) from healthy human donors was collected 
in tubes containing EDTA in accordance with the approval and 
ethical guidelines of the Universidad Michoacana de San Nicolás 
de Hidalgo. Blood was diluted in the same volume of RPMI 
medium. Then, 20  ml of diluted blood was carefully added to 
a tube containing 10  ml of Lymphoprep™ and centrifuged 
at 800 ×  g for 20  min at room temperature (23°C). The phase 
containing peripheral blood mononuclear cells (PBMC) was 
separated and washed 3× with enough PBS to complete 50 ml for 
each wash and centrifuged at 250 × g for 10 min. After washing, 
PBMC were resuspended in RPMI medium and seeded in six-
well plate at 2 × 106 cells/well. Cells were left resting for at least 
3 h before the experiments.
gene Knockdown of MsK1 and MsK2
MSK1 and MSK2 gene expression were silenced with siRNA 
acquired from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). The siRNA for MSK1 (sc-35978), MSK2 (sc-75837), and 
control siRNA (sc-37007) were added to macrophages at the final 
concentration of 40 nM for 48 h, according to the manufacturer’s 
instructions. To test for MSK1/MSK2 participation in CREB 
phosphorylation at Ser133, macrophages were first gene silenced 
for MSK1 and/or MSK2 and then stimulated with 20 μg/ml of 
IDR-1002 for 15 min.
Protein extraction and  
Western Blot analysis
The relative abundance of phosphorylated and non-phosphoryl-
ated proteins was evaluated in protein extracts from macrophages 
grown in six-well culture plates to ~90% confluence before serum 
starvation for at least 4 h. For each assay, total protein (cytosolic 
plus nuclear from control and treated cells) was obtained by 
washing cells with cold PBS (2×) and lysing them with 80  μl 
of a cold lysis buffer containing 20  mM Tris–HCl pH 7.5, 
150  mM NaCl, 1% Igepal CA-930, 10  mM Na-pyrophosphate, 
and 50  mM NaF, supplemented with 1  mM Na-orthovanadate 
and 1× protease inhibitor cocktail that was added immediately 
before use. The lysates were centrifuged at 13,000 × g for 20 min 
at 4°C, and the supernatant was transferred to ice-cold Eppendorf 
tubes. Nuclear and cytoplasmic fractions were prepared from 
cells using the NE-PER Reagent kit from Pierce (Rockford, IL, 
USA), and stored in aliquots at −80°C. Protein concentration was 
measured by the Bradford method (33) using BSA as standard. 
Then, 40 μg of protein was separated by electrophoresis in 10% 
sodium dodecyl sulfate polyacrylamide gels and electroblotted 
in a wet chamber to 0.45 μm nitrocellulose membrane (Bio-Rad) 
at 250–300 mA for 1 h. Membranes were then probed with the 
indicated antibody and the abundance of the phosphorylated and 
unphosphorylated forms of each protein was detected using the 
Immobilon Western Chemiluminescent HRP substrate kit from 
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Millipore (Billerica, MA, USA). Membranes were exposed to an 
X-ray film (Kodak) with two intensifying screens (DuPont) at 
room temperature (23°C).
co-immunoprecipitation assays
Macrophages Raw 264.7 were seeded in 10-cm cell plate culture 
until confluence, left in serum-free media for 4  h, and then 
stimulated as indicated. For immunoprecipitation technique, 
we use the kit Pierce™ Protein A/G Magnetic Beads (Thermo 
Fischer Scientific). In brief, ~1 × 107 cells were lysed in washing/
lysis buffer supplemented with 1× protease inhibitor cocktail, 
and cells debris were collected by centrifugation at 18,000 × g for 
10 min at 4°C. The supernatant was collected and quantified for 
protein concentration. Then, 4 μg of each immunoprecipitation 
antibody (CBP or IκBα) was added to 500 μg of protein extract 
and the volume adjusted to 500 μl. The mixture was incubated 
with continuous agitation all night at 4°C. Next day, 25 μg of 
magnetic beads were added and incubated 1  h in agitation at 
room temperature (23°C); beads were washed 2× with washing 
buffer and 1× with water. The target antigen was eluted with 
lane marker buffer 1× plus 50 mM DTT in the final volume of 
100 μl. For immunoblots, 20 μl of target antigen in elution buffer 
was used and detected as described in the western blot analysis 
section.
cytokine Quantitation
Mouse cytokines, IL-4, IL-6, IL-10, IL-13, TNF-α, and PGE2 
levels, were measured by ELISA, according to the manufacturer’s 
instructions (R&D, Minneapolis, MN, USA).
cytokine array
Macrophages were incubated for 1  h with 20 μg/ml of IDR-1, 
IDR-HH2, or IDR-1002 and then stimulated for 2–24  h with 
10  ng/ml of LPS. Supernatants were collected and cytokines 
were detected using a mouse cytokine antibody pair-based array 
spotted on a membrane (Abcam, ab133993) according to the 
manufacturer’s instructions (Cambridge, UK). Briefly, analysis 
of cytokines present in the macrophages supernatant is carried 
out by chemiluminescent western blot assay, using biotinylated 
detector antibodies and streptavidin HRP. Targets of this ELISA-
like array are granulocyte-colony stimulating factor (GCSF), 
granulocyte-macrophage colony stimulating factor (GM-CSF), 
IL-2, 3, 4, 5, 6, 9, 10, 12 p40/p70, 12p70, 13, 17, interferon gamma 
(IFN-γ), monocyte chemoattractant protein 1 and 5 (MCP-1 
and MCP-5), regulated on activation normal T cell expressed 
and secreted (RANTES), stem cell factor (SCF), soluble tumor 
necrosis receptor factor 1 (sTNFR1), tumor necrosis factor alpha 
(TNF-α), thrombopoietin, and vascular endothelial growth fac-
tor (VEGF).
statistical analysis
Statistical significance was evaluated using Student’s paired t-test 
using the SIGMASTAT program version 3.0 (SPSS Inc., Chicago, 
IL, USA). Band densitometric analysis was performed using the 
Image Processing and Analysis module in Java Program ImageJ 
(http://rsbweb.nih.gov/ij).
resUlTs
iDr-1002 reduced the lPs-induced 
expression of TnF-α and cOX-2
To explore the effect of IDR-1, IDR-HH2, and IDR-1002 on 
cytokine expression, we used an antibody array of 22 cytokines. 
After 12  h of incubation with each of the IDR peptides, we 
evaluated the level of cytokine expression in the supernatants. 
Compared to control (Figure 1A), IDR-1 had a modest effect on 
TNF-α expression (Figure  1B). However, when macrophages 
were treated with IDR-HH2 or IDR-1002, the basal levels of TNF-
α were significantly reduced. We observed that IDR-1002 was a 
somewhat stronger inhibitor than IDR-HH2 (Figures 1C,D). A 
map of the cytokine array is shown in Figure 1E. To determine 
the kinetics of the effect of IDR-1002 on TNF-α production, 
macrophages were pre-incubated with IDR-1002 for 1  h and 
then stimulated, for periods of 2–24 h, with LPS from E. coli, an 
agonist that induced a strong release of TNF-α. We observed that 
production of TNF-α activated by LPS was strongly reduced in 
the presence of IDR-1002 (Figure 1F). These results indicate that 
IDR-1002 had an inhibitory effect on the basal and LPS-induced 
expression of TNF-α.
Another important gene expressed in the inflammatory 
response and induced by LPS is COX-2. This enzyme catalyzes 
the conversion of arachidonic acid into prostaglandins and 
thromboxane, playing an important role in the inflammatory 
response (34). To determine the effect of IDR-1002 on COX-2 
production, macrophages were pre-incubated with IDR-1002 
for 1  h and then stimulated with LPS for a period of 2–24  h. 
Under this condition, we observed that COX-2 expression was 
strongly and significantly reduced in the presence of IDR-1002 
(Figure  2A). Incubation of macrophages with IDR-1002 alone 
for 2, 4, and 8 h did not have any effect on COX-2 (Figure 2B). 
These results indicate that IDR-1002 had an inhibitory effect on 
the LPS-induced expression of COX-2.
iDr-1002 reduced the Phosphorylation of 
nF-κB p65 subunit at ser536 and its 
nuclear Translocation
Activation of NF-κB stimulates its nuclear translocation leading 
to the expression of many pro-inflammatory genes, among which 
TNF-α and COX-2 play important roles in the inflammatory 
response. To explore if IDR-1002 inhibited TNF-α and COX-2 
expression by inhibiting NF-κB activity, we evaluated phospho-
rylation of the p65 subunit at Ser536 (a residue located in the 
transactivation domain), and its nuclear relative abundance. 
An ~20–40% reduction of p65 phosphorylation at Ser536 was 
observed when macrophages were incubated with IDR-1002 for 
5, 30, or 60 min (Figure 3A). Next, we investigated the relative 
abundance of p65 in the cytoplasm and nucleus of macrophages 
incubated with LPS and IDR-1002. From data shown in Figure 3B, 
it was clear that LPS stimulated p65 nuclear translocation, which 
was inhibited by IDR-1002. The co-immunoprecipitation of 
NF-κB and coactivator CBP was detected exclusively in mac-
rophages stimulated with LPS, but not in those stimulated with 
IDR-1002 followed by LPS or IDR-1002 alone (Figure 3C). These 
FigUre 1 | iDr peptides reduced the expression of TnF-α in raW 264.7 macrophages. Macrophages were left unstimulated (control) (a) or stimulated with 
20 μg/ml of IDR-1 (B), IDR-HH2 (c), or IDR-1002 (D) for 12 h. Conditioned media were then collected and centrifuged at 18,800 × g for 10 min. The supernatants 
were transferred to ice-cold tubes and stored at −80°C. Cytokine expression was evaluated with an antibody base-paired array kit (Abcam ab133993), in which 
antibodies against 22 different cytokines were spotted on a membrane. (e) Cytokines array map. In each array, the position of TNF-α is indicated with continuous-
line rectangles while positive controls are indicated with dashed-line rectangles. (F) Cells were left unstimulated (control), stimulated with 10 ng/ml LPS, or pretreated 
with 20 μg/ml IDR-1002 for 1 h followed by incubation with 10 ng/ml LPS for 2–24 h. Supernatants were collected and treated as described above. TNF-α 
quantitation was performed by ELISA (R&D), according to the manufacturer’s instructions. Data represent means ± SEM (n = 3). **P < 0.05 for LPS assays 
compared with the unstimulated control value. *P < 0.05 for 1002 + LPS assays compared with LPS treatment.
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results indicate that IDR-1002 reduced the relative abundance 
of p65 phosphorylated at Ser536 and its LPS-induced nuclear 
translocation and interaction with CBP.
iDr-1002 inhibited the Phosphorylation 
and Degradation of ikBα induced by lPs
In unstimulated cells, NF-κB is anchored to IκBα in the cyto-
plasm. Release of NF-κB requires phosphorylation of IκBα, 
which marks it to become ubiquitinated and then degraded in 
the proteosome. This mechanism implies that if phosphorylation 
of IκBα is inhibited, then NF-κB would not be released and its 
nuclear translocation would not occur. Our data indicate that 
IDR-1002 strongly inhibited the LPS-induced phosphorylation 
of IκBα (Figure 4A) and its degradation (Figure 4B). This effect 
of IDR-1002 on IκBα seemed to be independent of the stimulus 
because inhibition of IκBα phosphorylation and degradation by 
IDR-1002 was equally effective in macrophages stimulated with 
TNF-α or IL-1β (Figures 4A,B). Interaction of NF-κB p65 and 
IκBα was stabilized as a consequence of IDR-1002 inhibition of 
IκBα phosphorylation and degradation. Figure  4C shows that 
there was an increase in co-immunoprecipitation NF-κB p65 
bound to IκBα in macrophages stimulated with IDR-1002. These 
data may explain the inhibitory effect exerted by IDR-1002 on 
TNF-α and COX-2 expression.
activation of creB Phosphorylation at 
ser133 by iDr-1002 Was Dependent on 
erK1/2, p38, and MsK1 activity
A major mechanism for controlling the inflammatory response 
is the suppression of pro-inflammatory cytokine expression, 
which can be promoted when NF-κB forms a molecular complex 
with CBP (16, 17). This process takes place during the inflam-
matory response when CREB is also activated by phosphoryla-
tion at Ser133. Phosphorylation of CREB enables it to compete 
with NF-κB for the same interaction domain on CBP (18). The 
consequence of NF-κB separation from CBP is a reduction in 
inflammatory cytokine expression and simultaneously an incre-
ment, in many but not all cases, of anti-inflammatory cytokine 
expression due to CREB activity. To explore if IDR-1002 activated 
CREB phosphorylation at Ser133, macrophages were incubated 
with IDR-1002 for 5– 60  min. Under these conditions, a sig-
nificant increase in CREB phosphorylation was observed for up 
to 45  min of incubation with IDR-1002 (Figure  5A). Because 
CREB phosphorylation can be mediated by Akt (PKB), ERK1/2, 
FigUre 2 | iDr-1002 inhibited the lPs-induced cOX-2 expression in raW 264.7 macrophages. (a) Macrophages Raw 264.7 were left unstimulated (Ctrl), 
stimulated with 10 ng/ml of LPS, or pretreated with 20 μg/ml of IDR-1002 for 1 h followed by incubation with 10 ng/ml of LPS for 2–24 h. At the end of each 
incubation period, COX-2 was analyzed by Western blotting. Protein from Ctrl cells were collected at 4 h. A representative immunoblot of three independent 
experiments is shown. GAPDH detection was used as control to ensure equal protein loading. (B) At each indicated incubation time, COX-2 expression was 
measured in untreated control and IDR-1002-treated cells. Values were normalized with GAPDH as protein loading control. This graph is representative of two 
independent experiments. Data represent means ± SEM (n = 3). **P < 0.05 for LPS compared with the unstimulated control value. *P < 0.05 for 1002 + LPS 
compared with LPS treatment.
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p38, and MSK1/2, we performed experiments utilizing specific 
inhibitors for each one of these enzymes. Macrophages stimu-
lated with IDR-1002 showed an increased relative abundance of 
CREB phosphorylated at Ser133 and this was reduced by specific 
inhibitors of p38 and ERK1/2 (Figures 5B,C). Correspondingly, 
IDR-1002 induced a strong phosphorylation of ERK1/2 and p38 
(Figures S1A,B in Supplementary Material), as described previ-
ously (27). However, specific inhibitors of PI3K, GSK3, and Akt 
did not have any effect on CREB phosphorylation (Figures S2A,B 
in Supplementary Material).
Other authors have reported that ERK1/2 and p38 do not 
directly phosphorylate CREB but instead they first phosphoryl-
ate MSK1/2, which in turn phosphorylates CREB at Ser133 (35). 
To test if MSK1/2 linked the activation of ERK1/2 and p38 with 
CREB phosphorylation, we silenced the MSK1 and MSK2 genes 
using siRNA. When these genes were independently or simulta-
neously silenced, a significant reduction in CREB phosphoryla-
tion was observed (Figure 6A), which indicated that both MSK1 
and MSK2 could participate. However, only MSK1 (Figure 6B), 
but not MSK2 (data not shown), phosphorylation was detected 
in macrophages stimulated with IDR-1002. Evidence of MSK1 
gene knockout by siRNA is presented in Figure 6A. Furthermore, 
incubation of macrophages with either ERK1/2- or p38-specific 
inhibitors almost completely prevented phosphorylation of 
MSK1 (Figure 6B).
However, although CREB was strongly phosphorylated, we 
observed no increase in the anti-inflammatory cytokines IL-4, 
IL-10, and IL-13 as measured by ELISA (data not shown). The lack 
of expression of these cytokines associated with M2 macrophage 
response might be due to the absence of interaction between 
phosphorylated CREB and CBP. The co-immunoprecipitation of 
CREB with CBP from macrophages stimulated with IDR-1002 
showed that no complex was formed between CBP and CREB 
(Figure 6C). Together, these genetic and biochemical data indi-
cated that IDR-1002-induced phosphorylation of CREB at Ser133 
depended on the ERK1/2/p38–MSK1 signaling pathway, and 
that, at least in our system, phosphorylation of CREB by MSK1 
did not promote interaction between CREB and CBP.
FigUre 4 | iDr-1002 inhibited iκBα phosphorylation and degradation 
in raW 264.7 macrophages. (a) Macrophages were left unstimulated or 
pretreated with 20 μg/ml of IDR-1002 for 1 h. Then, macrophages were 
stimulated for 10 min with either 10 ng/ml of LPS, 10 ng/ml of TNF-α, or 
10 ng/ml of IL-1β. Phosphorylated IκBα was detected by Western blot 
analysis and β-actin was detected to ensure equal protein loading. (B) 
Macrophages were treated as in (a) except that incubation with LPS, TNF-α, 
or IL-1β was for 30 min. Total IκBα was detected by Western blot analysis in 
total cell lysates extracts. β-actin detection was performed to ensure total 
protein loading. (c) Macrophages were left unstimulated or stimulated with 
20 μg/ml of IDR-1002 for 1 h followed by stimulation with 10 ng/ml of LPS for 
10 min. IκBα was immunoprecipitated (IP) and eluates were subjected to 
Western blot to detect NF-κB p65 in the immunoprecipitates of IκBα (bound) 
or supernatants (unbound) samples (IB). β-actin detection was performed in 
the input cell extracts to ensure equal protein.
FigUre 3 | iDr-1002 reduced nF-κB p65 phosphorylation at ser536 
and inhibited its lPs-activated nuclear translocation in raW264.7 
macrophages. (a) Macrophages were left unstimulated (Ctrl) or stimulated 
with 20 μg/ml of IDR-1002 for 5–60 min. Phosphorylation of NF-κB p65 
subunit was detected by Western blotting. Detection of β-actin and 
unphosphorylated p65 in each sample was performed to ensure equal 
protein loading. (B) Macrophages were pretreated with 20 μg/ml of IDR-1002 
for 1 h and then with 10 ng/ml of LPS for 2 h. Non-phosphorylated NF-κB 
p65 subunit was detected by Western blotting in nuclear and cytosolic 
protein enriched fractions. Laminin A/C and β-actin were detected as 
controls for nuclear and cytosolic fractions, to observe equal protein loading 
and no cross-contamination between nuclear and cytosolic fractions, 
respectively. (c) Macrophages were treated as described in (B). Eluates from 
CBP immunoprecipitates (IP) were subjected to Western blot analysis with 
NF-κB p65 antibody to detect the p65 bound to CBP and its amount present 
in the input (IB). Control with isotype IgG was also included. Detection of 
CBP was performed to show equal protein loading. *P < 0.05 for IDR-1002 
compared with the unstimulated control value.
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DiscUssiOn
Data presented here demonstrated that in RAW264.7 mac-
rophages/monocytes stimulated with LPS, IDR-1002 was able 
to inhibit IκBα phosphorylation and degradation, completely 
blocking NF-κB p65 nuclear translocation. This would explain 
the inhibition of the interaction between NF-κB and CBP, and 
partially inhibition of NF-κB p65 Ser536-phosphorylation, 
which can enhance transactivation. These effects of IDR-1002 
on NF-κB p65, together with others previously reported (36, 37), 
were sufficient to reduce the expression of TNF-α and COX-2. 
In addition, IDR-1002 induced a significant increase in CREB 
phosphorylation at Ser133 through the activation of p38/ERK1/2 
and MSK1/2. Although the relative abundance of phosphorylated 
CREB was higher in macrophages stimulated with IDR-1002 than 
in untreated controls, no interaction between CREB and CBP 
occurred, and thereby preventing the enhanced expression of 
cytokines IL-4, IL-10, and IL-13.
Inhibition of TNF-α expression in RAW264.7 macrophages 
has been demonstrated by in  vitro administration of different 
compounds in response to LPS from E. coli (38–41). For example, 
the anti-inflammatory effect of extracellular phospho-ceramide 
analog-1 (PCERA-1) was found to depend on suppression of 
TNF-α production, an increase in cAMP levels, and increased 
expression of IL-10 (38). The low molecular weight chemical 
compounds madecassic and asiatic acid, and the isoflavone 
genistein potently inhibited the expression of TNF-α, COX-2, 
NO, prostaglandin E2, IL-1β, and IL-6 by blocking both IκBα 
FigUre 5 | inhibition of p38 and erK1/2 activity reduces creB 
phosphorylation at ser133 in raw 264.7 macrophages activated by 
iDr-1002. (a) Macrophages were left unstimulated (Ctrl) or stimulated with 
20 μg/ml of IDR-1002 for 5–60 min. After stimulation, CREB phosphorylation 
was detected by Western blotting. (B) Cells were left untreated (−) or treated 
with 5 μM of SB203580 (SB, a p38 inhibitor) for 30 min and then stimulated 
with 20 μg/ml of IDR-1002 for 15 min. (c) Cells were left untreated (−) or 
treated with 25 μM of PD98059 (PD, an ERK1/2 inhibitor) for 30 min and then 
stimulated with 20 μg/ml of IDR-1002 for 15 min. Additional controls in which 
cells were treated with 5 μM of SB or 25 μM of PD alone were also included. 
Phosphorylation of CREB was analyzed by Western blotting. Detection of 
β-actin and unphosphorylated CREB were performed to ensure equal protein 
loading. Blots are representative of three independent experiments. The data 
represent means ± SEM (n = 3). *P < 0.05 for IDR-1002 compared with the 
unstimulated control value. **P < 0.05 for inhibitor + IDR-1002 assays 
compared with the IDR-1002 assay.
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degradation and NF-κB nuclear translocation (39–41). The 
effects in macrophages induced by IDR-1002 on TNF-α/COX-2 
expression, and NF-κB inhibition, resemble those triggered 
by the compounds mentioned above, suggesting that parallel 
mechanisms mediate the effect of IDR-1002 to control inflam-
mation. Specifically, we found in RAW 264.7 macrophages that 
IDR-1002 was able to inhibit LPS-induced phosphorylation of 
IKKα and IKKβ, which may explain the inhibitory effect of this 
peptide on IκBα phosphorylation (Figure S3 in Supplementary 
Material). Recently, Liu et  al. (42) discovered that a long non-
coding RNA inhibits IκB phosphorylation by forming a ternary 
complex with NF-κB and IκBα, which caused a strong inhibition 
of metastasis in breast cancer. Based on these results, it is possible 
that IDR-1002, as an inhibitor of IKK and IκBα phosphorylation, 
may be a good candidate for metastasizing cancers. We are cur-
rently performing experiments to test IDR-1002 in various cancer 
cell lines.
COX-2 is important in the control of inflammation, pain, 
fever, and other physiological processes. Inhibition of COX-2 
activity by non-steroidal anti-inflammatory drugs (NSAIDs) 
such as aspirin has been the clinicians’ choice to alleviate medical 
conditions. However, NSAIDs induce tolerance over time (43) 
and administration for even short periods can cause gastroin-
testinal and renal secondary effects in ~25% of individuals and 
almost 5% of them suffer serious health problems (44). Because 
of these detrimental effects induced by NSAIDs, a search for 
new anti-inflammatory drugs without side effects is of primary 
importance in the pharmaceutical industry. The strong inhibi-
tion by IDR-1002 of LPS-induced COX-2 expression observed in 
our study suggests that IDR peptides may be a viable alternative. 
However, more experiments in vivo and chemical modification/
formulation of IDR-1002 to increase its potency, specificity, and 
half-life time must be considered before its administration to 
human beings.
Apart from the inhibitory effect of IDR-1002 on LPS-
induced NF-κB and COX-2, this cationic peptide induced the 
phosphorylation/activation of p38, ERK1/2, and MSK1, which 
led to the phosphorylation of CREB at its Ser133 activation site. 
The contribution of the signaling pathway PI3K/Akt/GSK3 as 
an effector of IDR-1002-induced CREB phosphorylation was 
ruled out (Figure S2 in Supplementary Material). According 
to one current model, once CREB becomes phosphorylated at 
Ser133, it is able to interact with CBP and induce expression 
of anti-inflammatory cytokine genes, among which IL-4, IL-10, 
and IL-13 are the most important for reducing inflammation 
(23). However, it has been documented that in some cases 
phosphorylation of CREB at Ser133 by MSK1/2 is not absolutely 
required to promote recruitment of CBP and, consequently, 
expression of some CREB target genes does not take place 
(15). Similarly, activation of T-cell receptor (TCR) promotes a 
strong phosphorylation of CREB at Ser133 without formation 
of CREB–CBP complex, unless low amounts of cAMP were 
present as a costimulus (24). In our case, IDR-1002-activated 
MSK1-dependent phosphorylation of CREB did not promote 
the interaction of CREB with CBP, which might explain lack of 
effects on gene expression of IL-4, IL-10, and IL-13. This conclu-
sion was drawn after several attempts to co-immunoprecipitate 
CBP with CREB in protein extracts recovered from macrophages 
stimulated with IDR-1002. More experiments to find out the 
FigUre 6 | MsK1-mediated creB phosphorylation at ser133 in raW 264.7 macrophages stimulated with iDr-1002. (a) Macrophages were transfected 
with non-specific siRNA control (Mock), MSK1 (siMSK1), MSK2 (siMSK2) or MSK1, and MSK2 simultaneously for 48 h. Cells were then stimulated with 20 μg/ml of 
IDR1002 for 15 min. CREB phosphorylation was analyzed by Western blotting. Detection of β-actin and unphosphorylated CREB in each sample was performed to 
ensure equal protein loading. The right panel shows detection of MSK1 gene expression when macrophages were treated with MSK1-specific siRNA. In (B), 
macrophages were left unstimulated (−) or pretreated with 25 μM of PD98059 (PD, an ERK1/2 inhibitor) and 5 μM of SB203580 (SB, a p38 inhibitor) for 30 min, and 
then stimulated with IDR-1002 for 15 min. Additional controls with 25 μM of PD and 5 μM of SB alone were also included. Under these conditions, phosphorylation 
of MSK1 was detected by Western blotting. (c) Macrophages were left unstimulated or stimulated with 20 μg/ml of IDR-1002 followed by stimulation with 10 ng/ml 
of LPS. Immunoprecipitation was performed as previously described and eluates from CBP immunoprecipitates (IP) were subjected to Western blot analysis with 
CREB antibodies. Then, we detected CREB immunoprecipitated (bound) with CBP and in the input (IB). Control with isotype IgG was also included. Detection of 
CBP was performed to show equal protein loading. The blots are representative of three independent experiments. Data represent means ± SEM (n = 3). *P < 0.05, 
compared with the unstimulated control value. **P < 0.05 for siRNA treatment compared with the IDR-1002 value.
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molecular details of this mechanism are currently underway in 
our laboratory.
The experimental evidence obtained in RAW 264.7 mac-
rophages indicating that IDR-1002 inhibits LPS-induced 
COX-2 expression, activates CREB phosphorylation at Ser133, 
and inhibits LPS-induced IκBα degradation was confirmed 
in PBMC (Figures S4A–C in Supplementary Material). This 
novel spatiotemporal combination of both effects (inhibition 
of NF-κB signaling and activation of CREB phosphorylation) 
makes IDR-1002 an attractive anti-inflammatory pharmaceuti-
cal drug.
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